Medication non-compliance is an epidemic that impacts patients, sponsors and the healthcare industry at large, costing the U.S. healthcare system around 300 billion dollars a year. According to a PM360 article that highlights medication compliance in diabetes patient populations, non-adherent patients have inpatient healthcare costs that are 41% higher than those of adherent patients.
Reimbursing patients should be easy. Yet, often enough, it is one of the most challenging programs for sponsors to implement. When comparing reimbursement options, make sure your program isn't lacking these five essentials.
It's not new to say that parents want the best for their kids – from education, opportunities, healthcare, and beyond. The same notion holds true in pediatric clinical studies.
Earlier this month, I presented BBK’s approach to advocacy outreach and engagement for patient recruitment at the inaugural Patients as Partners conference in Philadelphia, Penn., hosted by The Conference Forum. Patients as Partners examined how we engage with patients across the entire clinical trial continuum, including early research, patient-centric protocol design, recruitment, retention, and communicating results with patients acting as ambassadors and educators. Following the conference, I had an opportunity to interview Valerie Bowling, executive director at The Conference Forum. Here is what she had to say…
Years ago sponsors generally believed that site enrollment support simply involved developing generic outreach materials, mailing them out to each site and perhaps holding a brief training session on how to use the materials. It’s no wonder most studies failed to enroll on time. Today, most patient enrollment specialists, including BBK, define site enrollment support in terms of five broad areas of action.
A few years ago, I attended my brother's white coat ceremony for incoming medical students at the University of Medicine and Dentistry of New Jersey (UMDNJ), now Rutgers Medical School. The white coat ceremony contains much of the same pomp and circumstance of a college graduation; students march into a large white tent wearing their newly acquired white coats and are greeted by an array of family, friends, and faculty. The keynote speaker, the dean of students at the time, began her address by outlining the challenging, yet critical path that lay ahead.
Our colleagues at PharmaLive interviewed Matt Kibby, principal, technology and innovation, about the release of Study eBinder 3.0, the latest generation of our clinical trial management tool for on-the-go study teams. Click here to access the interview, or read below…
Ready. Set. Go.® Arrive Streamlines Travel for Clinical Trial Study Visits
I was in the dentist’s office this morning, waiting my turn, leafing through a copy of Smithsonian magazine, the July-August 2013 issue. I came across a short piece on page 20 that got me thinking about a number of things – including clinical trial patient retention.
Each and every review of a draft protocol by a study team, legal department, medical group, or regulatory agency is a test. Throughout this process it is easy to lose sight of what may well be the ultimate test of all – just, what does a protocol mean to a potential patient?
Analyzing a protocol from a patient recruitment perspective is imperative. When completed early in the protocol development stage, it can mean the cost-efficient addition of “patient-friendly” components that can significantly impact on-time enrollment. Consider the feasibility of:
- Minimizing patient time at study visits;
- Giving access to disease specialists;
- Offering an open-label option; or
- Providing concomitant medications or therapies at no cost